Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Open Access
- 2 February 2010
- Vol. 116 (S4), 1075-1083
- https://doi.org/10.1002/cncr.24795
Abstract
Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate‐specific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized IgG monoclonal antibody developed to target the extracellular domain of PSMA. Preclinical and early phase clinical studies using radiolabeled J591 have demonstrated efficacy in targeting tumor cells and decreasing levels of prostate‐specific antigen. Radiolabeled J591 is well‐tolerated, nonimmunogenic, and can be administered in multiple doses. The dose‐limiting toxicity is reversible myelosuppression with little nonhematologic toxicity. Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti‐PSMA radioimmunotherapy. Cancer 2010;116(4 suppl):1075–83. © 2010 American Cancer Society.Keywords
This publication has 70 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse AntibodyClinical Cancer Research, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaThe New England Journal of Medicine, 2005
- Combined modality radioimmunotherapyCancer, 2002
- Apoptosis induced by low-dose and low-dose-rate radiationCancer, 2002
- Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67Cu-2IT-BAT-Lym-1 RadioimmunotherapyCancer Biotherapy & Radiopharmaceuticals, 2001
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995
- Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogsNuclear Medicine and Biology, 1993
- Investigation of taxol as a potential radiation sensitizerCancer, 1993